Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) insider Dan Karlin sold 6,578 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $9.50, for a total value of $62,491.00. Following the sale, the insider now directly owns 358,452 shares in the company, valued at approximately $3,405,294. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Mind Medicine (MindMed) Trading Down 5.5 %
Shares of Mind Medicine (MindMed) stock opened at $9.86 on Wednesday. The business has a 50 day moving average price of $5.88 and a 200 day moving average price of $4.19. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.22 and a quick ratio of 3.22. The company has a market capitalization of $407.51 million, a P/E ratio of -4.02 and a beta of 2.65. Mind Medicine has a 1 year low of $2.41 and a 1 year high of $11.10.
Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.11). Sell-side analysts anticipate that Mind Medicine will post -1.7 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Ratings Changes
Several brokerages have recently commented on MNMD. Royal Bank of Canada boosted their price target on Mind Medicine (MindMed) from $14.00 to $15.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th. HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of Mind Medicine (MindMed) in a research report on Thursday, March 14th. Finally, Canaccord Genuity Group assumed coverage on Mind Medicine (MindMed) in a research report on Tuesday, December 5th. They set a “buy” rating and a $9.00 price objective for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $24.83.
Get Our Latest Stock Report on MNMD
About Mind Medicine (MindMed)
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder.
See Also
- Five stocks we like better than Mind Medicine (MindMed)
- Quiet Period Expirations Explained
- 3 Stocks With Unusual Call Option Activity
- How to Invest in Blue Chip Stocks
- Trump Media & Technology Group Soars on Market Debut
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 3 Stocks Insiders Are Buying That Analysts Love
Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.